SLX 1046
Alternative Names: SLX-1046Latest Information Update: 18 Jan 2024
At a glance
- Originator Biolexis Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action EIF2AK4 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Jan 2024 Biolexis Therapeutics plans to file IND application for Cancer in Q1 2025 (Biolexis Therapeutics pipeline, January 2024)
- 18 Jan 2024 Biolexis Therapeutics plans a phase I trial for Cancer in Q2 2025 (Biolexis Therapeutics pipeline, January 2024)
- 10 Oct 2023 Preclinical trials in Cancer in USA (unspecified route), before October 2023 (Biolexis Therapeutics pipeline, October 2023)